

[Open Peer Review on Qeios](#)

# Recombinant Anti-WT1 Immunotherapeutic GSK2302024A

National Cancer Institute

## Source

National Cancer Institute. *Recombinant Anti-WT1 Immunotherapeutic GSK2302024A*.  
NCI Thesaurus. Code C116880.

An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.